Galectin Therapeutics (GALT) EBITDA (2010 - 2026)
Galectin Therapeutics (GALT) recorded quarterly EBITDA of -$4.1 million in Q1 2026, down 21.16% quarter-over-quarter from -$3.4 million in Q4 2025, and up 48.37% on a YoY basis from -$2.7 million in Q1 2025.
Galectin Therapeutics (GALT) EBITDA (2010 - 2026) Analysis & Trends
Galectin Therapeutics' EBITDA history runs 17 years deep, the most recent figure standing at -$4.1 million for Q1 2026.
- In Q1 2026, EBITDA rose 48.37% year-over-year to -$4.1 million; the TTM figure through Mar 2026 stood at -$16.3 million (up 60.02% YoY), while the FY2025 annual figure was -$20.1 million, up 52.67% from the prior year.
- EBITDA was -$4.1 million for Q1 2026 at Galectin Therapeutics, down from -$3.4 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$3.4 million in Q4 2025 to a low of -$12.4 million in Q4 2024.
- Historically, EBITDA has averaged -$8.4 million across 5 years, with a median of -$9.2 million in 2023.
- The sharpest annual moves came in 2022 and 2025: EBITDA tumbled 57.27% in 2022, then surged 72.92% in 2025.
- A 5-year view of EBITDA shows it stood at -$10.6 million in 2022, then increased by 10.08% to -$9.6 million in 2023, then declined by 29.99% to -$12.4 million in 2024, then soared by 72.92% to -$3.4 million in 2025, then dropped by 21.16% to -$4.1 million in 2026.
- The last three EBITDA figures came in at -$4.1 million (Q1 2026), -$3.4 million (Q4 2025), and -$4.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Galectin Therapeutics | 185.83 Mn | 171.73 Mn | - | -4.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.08 Mn |
| Dec 31, 2025 | -3.37 Mn |
| Sep 30, 2025 | -4.20 Mn |
| Jun 30, 2025 | -4.63 Mn |
| Mar 31, 2025 | -7.90 Mn |
| Dec 31, 2024 | -12.43 Mn |
| Sep 30, 2024 | -9.07 Mn |
| Jun 30, 2024 | -11.29 Mn |
| Mar 31, 2024 | -9.65 Mn |
| Dec 31, 2023 | -9.56 Mn |
| Sep 30, 2023 | -9.17 Mn |
| Jun 30, 2023 | -9.00 Mn |
| Mar 31, 2023 | -10.34 Mn |
| Dec 31, 2022 | -10.63 Mn |
| Sep 30, 2022 | -8.12 Mn |
| Jun 30, 2022 | -9.66 Mn |
| Mar 31, 2022 | -9.94 Mn |
| Dec 31, 2021 | -7.43 Mn |
| Sep 30, 2021 | -8.24 Mn |
| Jun 30, 2021 | -8.19 Mn |